Optimal immunosuppressive therapy, defined clinically and by therapeutic drug monitoring (TDM), is essential to prevent acute rejection and ensure long-term survival of both the patient and the allograft. Characterized by a narrow therapeutic window, the use of immunosuppressive drugs (ISDs) requires both precise and consistent measurement of their concentration in whole blood during life-long monitoring.1
Consolidation for optimized workflow
The full ISD menu available on one automated and integrated Roche SWA platform:
- Best-in-class automated MPA (Mycophenolic Acid) available on cobas c modules2
- Elecsys Cyclosporine and Tacolimus now completed with Sirolimus and Everolimus on cobas e modules
One universal pre-treatment procedure for all ISD assays increase efficiency, ensure high quality results for every product and reduce handling errors in the lab
Outstanding possibilities for consolidation with >230 parameters on one cobas® platform
High precision for confidence in results
- High precision at low drug concentrations and across a wide measuring range
- Excellent performance confirmed in routine customer laboratories3
Consistent results for life-long monitoring
- Excellent lot-to-lot comparability and traceability
- Consistent patient results across all cobas® platforms due to universal reagent concept
- Low variability across different customer labs proven in external quality schemes3
- High comparability to well established and validated LC-MS/MS